Clinical trial
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
NCT00421954 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00421954 |
|---|---|
| Title | Open-label Ziprasidone Study for Psychosis Treatment in Adolescents |
| Official title | Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Ziprasidone |
| Enrollment | 8 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Jan 15, 2007 |
| Last update posted | Jan 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: